Pfizer dividend outlook assessed amid patent expirations
Cash flow metrics and strategic pivots offset revenue risks from upcoming patent cliffs, though the stock was excluded from The Motley Fool’s top 10 picks.
An analysis of Pfizer’s dividend sustainability indicates that its 6.7 per cent yield, while significantly higher than the S&P 500’s 1.1 per cent and the pharmaceutical sector average of 1.7 per cent, is underpinned by management’s explicit commitment to maintaining payments. This commitment is prioritised alongside research and development investments to maximise post-2028 growth, as outlined in the company’s first-quarter earnings materials.
Although the earnings-based payout ratio stands at 130 per cent, the cash flow-based payout ratio is just over 100 per cent, and the company’s debt-to-equity ratio of 0.7x remains lower than competitor Eli Lilly’s 1.4x. To mitigate revenue declines from upcoming patent expirations, Pfizer has pivoted strategically, including acquiring a company with a promising GLP-1 candidate after cancelling its own weight-loss drug, and entering partnerships with Chinese firms for GLP-1 and oncology treatments.
The S&P 500 index has a dividend yield of 1.1 per cent, while the average pharmaceutical company yield is 1.7 per cent, making Pfizer’s 6.7 per cent yield appear unusually high by comparison. Patent expirations are a standard operational risk for pharmaceutical companies, often creating timing mismatches between revenue drops and new drug development cycles.
Eli Lilly is currently benefiting from significant revenue growth in its GLP-1 drugs Mounjaro and Zepbound, with sales rising 125 per cent and 80 per cent respectively in the first quarter of 2026. Historical performance data from The Motley Fool highlights past successful stock picks, such as Netflix and Nvidia, to illustrate potential returns from their recommended lists.
The Motley Fool’s Stock Advisor analyst team did not include Pfizer in their current list of 10 best stocks to buy, despite the article arguing the dividend is safer than perceived. The Motley Fool has positions in and recommends Eli Lilly and Pfizer.
Pfizer dividend Eli Lilly GLP-1 patent expiration Pfizer Eli Lilly Motley Fool S&P 500
